BC
CLVS

Bridgefront Capital’s Clovis Oncology, Inc. CLVS Stock Holding History

Bridgefront Capital’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-27,872
Closed -$162K – 732
2021
Q2 		$162K Sell
27,872
-26,425
-49% -$155K 0.06% 524
2021
Q1 		$381K Buy
+54,297
New +$364K 0.12% 342

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bridgefront Capital's CLVS Position: Q3 2021 in Review

Bridgefront Capital sold out of Clovis Oncology, Inc. (CLVS) in Q3 2021, closing a stake of 27,872 shares — an estimated $162K sold.

Bridgefront Capital first reported a position in CLVS in Q1 2021 and held it in 2 quarters. The position peaked at $381K in Q1 2021. 157 funds tracked by Wall St. Rank hold CLVS as of Q3 2021.

  • Bridgefront Capital reported no remaining Clovis Oncology, Inc. position as of Q3 2021 after selling out during the quarter.
  • Bridgefront Capital sold 27,872 Clovis Oncology, Inc. shares in Q3 2021, an estimated $162K.
  • Bridgefront Capital first reported a position in Clovis Oncology, Inc. in Q1 2021 and held it in 2 quarters.
  • Bridgefront Capital's Clovis Oncology, Inc. position peaked at $381K in Q1 2021.
  • 157 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2021.

Based on Bridgefront Capital's 13F filing for Q3 2021, filed 12 Nov 2021.